Active ingredientZasocitinibCat. No. P-Z008-001CAS 2272904-53-5Family · Pharmaceutical analytical standards
Zasocitinib
An oral, allosteric inhibitor of the enzyme TYK2, involved in signalling by cytokines such as IL-23; it has been studied in psoriasis, psoriatic arthritis and Crohn's disease, with positive phase 3 results in plaque psoriasis announced in late 2025. This family brings together the active ingredient and other impurities.
Did you know?In laboratory tests it proved more than a million times more selective for TYK2 than for its cousins JAK1, JAK2 and JAK3, enzymes of the same family.
Go to the active ingredient →Active ingredientZasocitinibCat. No. P-Z008-001CAS 2272904-53-5
ImpurityZasocitinib Impurity 1Cat. No. P-Z008-002CAS 2469042-39-3
ImpurityZasocitinib Impurity 2Cat. No. P-Z008-003CAS 2271470-66-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.